You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Medtronic
Merck
Baxter
Colorcon
Moodys
AstraZeneca

Last Updated: February 28, 2021

DrugPatentWatch Database Preview

LEVO-T Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

When do Levo-t patents expire, and what generic alternatives are available?

Levo-t is a drug marketed by Cediprof Inc and is included in one NDA. There is one patent protecting this drug.

This drug has eight patent family members in seven countries.

The generic ingredient in LEVO-T is levothyroxine sodium. There are ten drug master file entries for this compound. Thirty-seven suppliers are listed for this compound. Additional details are available on the levothyroxine sodium profile page.

Drug patent expirations by year for LEVO-T
Drug Prices for LEVO-T

See drug prices for LEVO-T

Pharmacology for LEVO-T
Drug Classl-Thyroxine

US Patents and Regulatory Information for LEVO-T

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Cediprof Inc LEVO-T levothyroxine sodium TABLET;ORAL 021342-001 Mar 1, 2002 AB1,AB2,AB3 RX No No   Start Trial   Start Trial   Start Trial
Cediprof Inc LEVO-T levothyroxine sodium TABLET;ORAL 021342-007 Mar 1, 2002 AB1,AB2,AB3 RX No No   Start Trial   Start Trial   Start Trial
Cediprof Inc LEVO-T levothyroxine sodium TABLET;ORAL 021342-004 Mar 1, 2002 AB1,AB2,AB3 RX No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for LEVO-T

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Cediprof Inc LEVO-T levothyroxine sodium TABLET;ORAL 021342-001 Mar 1, 2002   Start Trial   Start Trial
Cediprof Inc LEVO-T levothyroxine sodium TABLET;ORAL 021342-004 Mar 1, 2002   Start Trial   Start Trial
Cediprof Inc LEVO-T levothyroxine sodium TABLET;ORAL 021342-009 Mar 1, 2002   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim
Johnson and Johnson
AstraZeneca
Moodys
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.